Trial reportPloS one2016
Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis.
Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Proton pump inhibitor use: systematic review of global trends and practices.European journal of clinical pharmacology · 2023Pooled it
- Medications and Prescribing Patterns as Factors Associated with Hospitalizations from Long-Term Care Facilities: A Systematic Review.Drugs & aging · 2018Pooled it
- Proton pump inhibitor exposure modulates functional and transcriptional responses inFrontiers in cellular and infection microbiology · 2026Article
- Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases.Medicine · 2025Article
- Article
- Innovations in pharmacovigilance studies of medicines in older people.British journal of clinical pharmacology · 2025Review
- Proton pump inhibitors and gastrointestinal symptoms among patients with COVID-19 infection.Annals of medicine · 2024Article
- Genomic and clinical characteristics of campylobacteriosis in Australia.Microbial genomics · 2024Article
- Case Report: The importance of early intervention for gastroesophageal reflex disease caused by hiatal hernia.Frontiers in pediatrics · 2024Article
- Gastroesophageal reflux disease in children: What's new right now?World journal of gastrointestinal endoscopy · 2023Review
- A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps.Pharmacogenomics and personalized medicine · 2023Review
- Bringing pharmacomicrobiomics to the clinic through well-designed studies.Clinical and translational science · 2022Article
- Risk factors for campylobacteriosis in Australia: outcomes of a 2018-2019 case-control study.BMC infectious diseases · 2022Article
- Characterization of potentially inappropriate medication prescriptions for the elderly in primary care and hospital settings.Journal of family medicine and primary care · 2021Article
- Proton Pump Inhibitors and Infection-Related Hospitalizations Among Residents of Long-Term Care Facilities: A Case-Control Study.Drugs & aging · 2019Article
- Characteristics of Campylobacter and Salmonella Infections and Acute Gastroenteritis in Older Adults in Australia, Canada, and the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Expert opinion on drug metabolism & toxicology · 2018Review
- The zoonotic potential of Clostridium difficile from small companion animals and their owners.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo quantify the association between PPI use, type and dose and infectious gastroenteritis hospitalization in a population-based cohort of middle-aged and older adults.
methodsProspective study of 38,019 concession card holders followed up over 6 years in the Sax Institute's 45 and Up Study. Data from the baseline questionnaire were linked to prescription medication, hospitalization, notifiable disease, cancer registry and death datasets from 2006-2012. Associations between PPI use and gastroenteritis hospitalization were examined using Cox regressions with age as the underlying time variable.
resultsAmong 38,019 participants, the median age was 69.7 years, and 57.3% were women. Compared to non-users, current PPI users were more likely to be older, and have a higher BMI. During follow-up there were 1,982 incident gastroenteritis hospitalizations (crude rate: 12.9 per 1000 person-years, 95% CI: 12.3-13.5). PPI use was significantly associated with infectious gastroenteritis hospitalization (aHR 1.4, 95% CI: 1.2-1.5). Among current users, a dose-response relationship was observed between the average daily dose (DDD) dispensed per day and infectious gastroenteritis hospitalization (Ptrend<0.001). We also observed higher rates of infectious gastroenteritis hospitalization and greater PPI use among participants with a history of chronic bowel problems (aHR 2.2, 95% CI: 1.9-2.5). There was no difference in risk by type of PPI. Recent use of H2 receptors was not associated with gastroenteritis hospitalization.
conclusionPPI use is associated with an increased risk of infectious gastroenteritis hospitalization. Clinicians should be aware of this risk when considering PPI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.